ConductScience.org, home

Gene · 64115

VSIR: V-set immunoregulatory receptor

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. VSIR: V-set immunoregulatory receptor. Genes, record 64115. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/64115

On this page

Gene

Symbol
VSIR
HGNC
Name
V-set immunoregulatory receptor
HGNC
NCBI Gene ID
64115
NCBI Gene
HGNC ID
HGNC:30085
HGNC
Ensembl
ENSG00000107738
NCBI Gene
Aliases
B7-H5, B7H5, C10orf54, DD1alpha, Dies1, GI24, PD-1H, PP2135, SISP1, VISTA
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9H7M9V-type immunoglobulin domain-containing suppressor of T-cell activation3114Ensembl, GeneID, HGNC

Source UniProt

Patents305

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4808571 A12026-09-231Q9H7M9Espacenet
EP 4762092 A12026-06-2428Q9H7M9Espacenet
JP 2025174969 A2025-11-281Q9H7M9Espacenet
EP 4650780 A22025-11-1911216Q9H7M9Espacenet
WO 2025223455 A12025-10-3052Q9H7M9Espacenet
JP 2025147176 A2025-10-0614653Q9H7M9Espacenet
JP 2025531788 A2025-09-2563Q9H7M9Espacenet
EP 4619424 A22025-09-2422Q9H7M9Espacenet
JP 2025529142 A2025-09-045246Q9H7M9Espacenet
US 12384828 B22025-08-1262Q9H7M9Espacenet

1 to 10 of 305

See all 305 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,309

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleVSIR papersNewest fiscal year
P30CA016672Cancer Center Support Grant312025
P30CA008748Cancer Center Support Grant232025
P30CA023108Cancer Center Support Grant132025
P30CA016359Cancer Center Support Grant122025
P50CA196530Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer102025
UL1TR001863Yale Clinical and Translational Science Award102025
P50CA101942DF/HCC Kidney Cancer SPORE (supplement)92025
P30CA006973Regional Oncology Research Center72025
P30CA016056Roswell Park Cancer Center Support Grant52025
P30CA138292Winship Cancer Institute Cancer Center Support Grant52025

1 to 10 of 1,309Source NIH's project files

See all 1,309 nih grants

Papers2,513

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Hypoxia-inducible Factor 1-α: A Key Regulator of Immune Checkpoint Receptors in Acute Myeloid Leukemia Cell Lines.Iran J Allergy Asthma Immunol202642825905PubTator, text miningPubMed
Targeting VISTA as a novel immunotherapy for skin cancer.Front Immunol202642824772PubTator, text miningPubMed
Thymic neuroendocrine tumours: molecular landscape, immune microenvironment and therapeutic perspectives.Eur Respir Rev202642778205PubTator, text miningPubMed
Molecular Architecture and Clinical Landscape of Immune Checkpoint Receptors and Ligands.Antibodies (Basel)202642776797PubTator, text miningPubMed
Comparative pathogenesis, tissue tropism, and immune dynamics of infectious bronchitis virus genotypes GI‑1 and GI‑24 in broiler chickens.Poult Sci202642772140PubTator, text miningPubMed
VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications.Med Oncol202642742895PubTator, text miningPubMed
Next-Generation Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Mechanisms, Resistance, and Emerging Therapeutic Strategies.Cancers (Basel)202642649907PubTator, text miningPubMed
Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.Nat Commun202642649211PubTator, text miningPubMed
Linoleic acid metabolic reprogramming is linked to immunometabolic remodeling and post-transplant recurrence risk in hepatocellular carcinoma.Front Immunol202642643672PubTator, text miningPubMed
Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study.Immunotargets Ther202642639079PubTator, text miningPubMed

1 to 10 of 2,513

See all 2,513 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/64115

GET https://conductscience.org/api/genes/v1/64115/patents?page=2